Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ovarian cancer].

Toru Sugiyama1

  • 1Dept. of Obstetrics and Gynecology, Iwate Medical University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Most ovarian cancer patients need second-line therapy after initial treatment. Treatment strategies differ for sensitive versus resistant recurrent tumors, focusing on survival prolongation or alternative drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of lymphadenectomy in patients with advanced ovarian clear cell carcinoma: an ancillary analysis of the JGOG3017-A4 study.

International journal of clinical oncology·2025
Same author

Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G<sub>2</sub>/M phase in ovarian cancer.

Scientific reports·2024
Same author

Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

Journal of gynecologic oncology·2024
Same author

Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.

International journal of clinical oncology·2024
Same author

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study).

Cancers·2023
Same author

Isolation and identification of the new baicalin target protein to develop flavonoid structure-based therapeutic agents.

Bioorganic & medicinal chemistry·2023
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Pharmacology

Context:

  • Ovarian cancer treatment often involves surgery and paclitaxel/carboplatin (TJ) therapy.
  • A significant majority of patients (over 60%) require subsequent treatment lines.
  • Emerging strategies include intensified primary chemotherapy and neoadjuvant chemotherapy (NAC) followed by interval debulking surgery.

Purpose:

  • To outline current and emerging treatment paradigms for ovarian cancer, particularly focusing on second-line therapies.
  • To differentiate treatment approaches based on tumor recurrence sensitivity to paclitaxel/carboplatin (TJ) therapy.
  • To highlight the challenges and considerations in managing resistant ovarian cancer recurrence.

Summary:

  • For sensitive recurrent ovarian cancer, retreatment with paclitaxel/carboplatin (TJ) therapy combined with platinum agents is recommended, offering a response rate over 60% and prolonged survival.

Related Experiment Videos

  • For resistant recurrent ovarian cancer, alternative agents without cross-resistance to TJ therapy are necessary, though response rates are limited (12-32%) with shorter survival (approx. 8 months).
  • The abstract underscores the need for physicians to be adept in both chemotherapy and palliative medicine for managing advanced ovarian cancer.

    • Impact:

    • Informs clinical decision-making for second-line ovarian cancer treatment based on recurrence patterns.
    • Highlights the limitations of current therapies for resistant ovarian cancer, emphasizing the need for novel drug development.
    • Stresses the importance of integrating palliative care into the management of ovarian cancer patients facing treatment resistance and limited survival.